Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome

Teva Submits NDA for Ecopipam in Pediatric Tourette Syndrome

Teva Pharmaceutical Industries Ltd. announced the submission of a New Drug Application (NDA) to the U.S. FDA for ecopipam, an investigational first-in-class therapy for pediatric Tourette syndrome. This submission is supported by positive Phase 3 data published in JAMA Neurology, which demonstrated that ecopipam significantly delayed time to relapse compared to placebo (p = 0.008) in pediatric patients who had achieved a clinical response. Ecopipam, a selective dopamine D1 receptor antagonist, has received FDA Orphan Drug and Fast Track designations, potentially offering the first FDA-approved treatment option for this patient population in over a decade.

• Teva's NDA submission for ecopipam marks a significant step towards addressing a critical unmet need in pediatric Tourette syndrome. If approved, ecopipam could be the first new FDA-approved treatment for this chronic neuro-developmental disorder in over a decade, offering a novel option for patients who currently experience inadequate treatment control or limiting side effects with existing therapies. This submission aligns with Teva's "Pivot to Growth" strategy.
• The NDA is underpinned by robust Phase 3 clinical data, recently published in JAMA Neurology. The study demonstrated that ecopipam achieved a statistically significant benefit on its primary efficacy endpoint, showing a delayed time to relapse (p = 0.008) compared to placebo in pediatric patients with Tourette syndrome who had initially responded to open-label treatment. This key finding highlights the drug's potential to provide sustained therapeutic benefit.
• Ecopipam is a first-in-class selective dopamine D1 receptor antagonist, targeting D1 receptor hypersensitivity believed to contribute to repetitive behaviors in Tourette syndrome. The drug has also received FDA Orphan Drug and Fast Track designations, underscoring its potential importance for a rare disease population. In the Phase 3 study, ecopipam was generally well-tolerated, with common adverse events including somnolence, anxiety, headache, insomnia, tic, and fatigue.

Ecopipam NDA: Addressing a Decade-Long Gap in Pediatric Tourette Treatment

Over the past five years, the pediatric Tourette syndrome (TS) treatment landscape has been shaped by a clearer delineation of first-line versus escalation therapies, underpinned by evolving clinical trial evidence. Comprehensive Behavioral Intervention for Tics (CBIT) and Exposure and Response Prevention (ERP) remain the cornerstone first-line approaches, with strong evidence supporting their efficacy. Intensive group-delivered ERP demonstrated significant improvements on both the Yale Global Tic Severity Scale (YGTSS) and the Giles de la Tourette Syndrome Quality of Life Scale for Children and Adolescents, with 35% of children achieving reliable improvement on the YGTSS Global Tic Severity score and moderate-to-large effect sizes observed. Neuroimaging data have further refined understanding of treatment response mechanisms, with baseline functional connectivity between the right superior frontal gyrus and right angular gyrus identified as a predictor of vocal tic severity reduction following CBIT. Despite this evidence base, access to behavioral therapy remains limited, and caregiver-physician alignment on treatment decision-making continues to be an area of tension — 76% of caregivers preferred to direct final treatment decisions, while 80% of physicians favored equal or physician-directed models.

On the pharmacotherapy front, dopamine-modulating agents and alpha-2 agonists remain the most commonly used drug classes, with prescribing practices reflecting heterogeneity in clinical presentation and comorbidity burden. Real-world data from an Indian tertiary care cohort demonstrated that 82% of pediatric TS patients received pharmacotherapy, with risperidone most frequently prescribed, followed by clonidine, haloperidol, and aripiprazole — achieving moderate-to-significant improvement in 88% of cases. Emerging pharmacological options including vesicular monoamine transporter-2 (VMAT2) inhibitors have demonstrated favorable safety and effectiveness profiles in real-world use and open-label trials, though they have not consistently met primary endpoints in placebo-controlled settings. Topiramate and botulinum toxin injections represent additional options when first- and second-line agents are insufficient. Complicating treatment selection, 94% of pediatric TS patients carry at least one comorbid diagnosis — most commonly ADHD — and comorbid OCD and depression have been identified as significant predictors of increased tic severity, necessitating individualized, dynamically monitored pharmacotherapeutic strategies.

Among the most clinically significant recent developments is the investigation of ecopipam, a selective dopamine D1/D5 receptor antagonist, in a Phase 2b randomized controlled trial and 12-month open-label extension involving 133 children and adolescents with TS. Results showed that 63.2% of participants demonstrated improvement on the Clinical Global Impression of TS Severity (CGI-TS-S), 78.2% on the CGI-TS-I, and approximately two-thirds achieved the minimal clinically important difference (MCID) on the YGTSS Total Tic Score — with a 25% reduction in YGTSS scores established as the appropriate threshold for clinically meaningful improvement. A pilot open-label trial of medicinal cannabis (Δ9-THC:CBD at a 10:15 ratio) in adolescents aged 12–18 years also reported statistically significant improvements in tic severity, behavioral and emotional outcomes, and quality of life, though the authors acknowledged the need for larger randomized controlled trials to validate these findings. Collectively, these developments signal a broadening of the investigational pipeline for pediatric TS, at a moment when the unmet need for well-tolerated, efficacious pharmacological options — particularly in younger patients — remains substantial.

Unmet Needs and Limitations in Pediatric Tourette Syndrome Care

Current treatment approaches for pediatric Tourette syndrome (TS) face a convergence of clinical, logistical, and evidence-based challenges that collectively limit optimal patient outcomes. Despite advances in both behavioral and pharmacological therapies, no single intervention reliably eliminates tics, and meaningful gaps persist across access, personalization, and comorbidity management.

• Partial efficacy and symptom-focused goals: Pharmacotherapy for tic disorders is designed to reduce tic severity sufficiently to improve daily functioning and health-related quality of life — not to eliminate symptoms entirely. First-generation antipsychotics (SMD −0.65, low certainty), second-generation antipsychotics (SMD −0.71, moderate certainty), and α-2 agonists (SMD −0.21, moderate certainty) each outperform placebo, yet evidence certainty remains low to moderate across tolerability and acceptability comparisons.

• Lack of consensus in clinical guidelines: No agreement exists among clinical practice guidelines regarding which medications should be initially offered to children and young people with TS. Current recommendations rely largely on limited trial data and expert opinion, with dopamine-modulating agents and alpha-2 agonists most commonly used, and real-world effectiveness and generalizability of individual agents remaining open questions.

• Accessibility barriers to behavioral therapy: Evidence-based behavioral interventions — including habit reversal training and Comprehensive Behavioral Intervention for Tics (CBIT) — are insufficiently available in community settings. In a home-based parent-administered study, only 18 of 44 enrolled children completed the protocol, highlighting treatment dropout as a significant barrier; early telephone contact was identified as a potential strategy to improve retention.

• Challenges in personalizing treatment: The breadth of the TS clinical spectrum renders each patient phenotypically distinct, making personalized treatment both necessary and difficult to achieve. The absence of large prospective cohorts limits the identification of prognostic factors and the development of disease-modifying interventions.

• Comorbidity burden and its clinical implications: Comorbidities in TS are the rule rather than the exception, substantially shaping clinical presentation, disease severity, and quality of life. Both tic severity and co-occurring psychiatric disorders — including depression, anxiety, OCD, and autism spectrum disorders — may independently warrant active treatment, yet their co-presence complicates management decisions.

• Diagnostic complexity in the context of neurodevelopmental overlap: Tic identification is particularly challenging in individuals with autism spectrum disorder (ASD), where motor stereotypies can obscure or mimic tics. Intellectual disability further compounds assessment, given associated communication difficulties and overlapping behavioral presentations.

• Decision-making complexity in medication selection: Shared decision-making must account for tic-related distress and functional impairment, the efficacy-safety trade-offs between antipsychotics and α-2 agonists, and individualized patient factors that current trial-level analyses cannot fully address — placing considerable interpretive burden on clinicians and caregivers.

Ecopipam's Phase 3 Data: Efficacy and Safety Outcomes

The Medicinal Cannabis Trial (2025) was an open-label, single-arm feasibility study evaluating Δ9-tetrahydrocannabinol:cannabidiol (THC:CBD) at a 10:15 ratio in adolescents aged 12–18 years with Tourette syndrome, with dosing ranging from 5 to 20 mg/day based on body weight and clinical response. The trial demonstrated a favorable safety profile with no serious adverse events; the most commonly reported adverse effects were tiredness, drowsiness, and dry mouth. Efficacy outcomes were encouraging, with statistically significant improvements observed in parent- and clinician-reported tic severity (paired t-test P = 0.003), behavioral and emotional outcomes (P = 0.048), and quality of life as reported by both parents and young people (P = 0.027 and P = 0.032, respectively). The authors concluded that a larger-scale randomized controlled trial is warranted to validate these preliminary findings.

The Ecopipam Phase 2b Trial (2026) was a randomized controlled trial with a 12-month open-label extension conducted in children and adolescents with Tourette syndrome. The intervention under investigation was ecopipam, an investigational agent not currently FDA-approved for Tourette syndrome. The study was designed to evaluate whether ecopipam could safely improve tic symptoms and quality of life in a pediatric population, though granular safety and efficacy outcome data were not fully detailed in the available literature. The ORBIT-UK Study (2026) was a single-cohort usability trial enrolling 20 children and young people aged 9–17 years alongside their chosen supporters. The intervention consisted of a 10-week online Exposure and Response Prevention (ERP) program supported by trained coaches and delivered via an NHS-compliant platform. Clinical outcomes were assessed using the Yale Global Tic Severity Scale, the Parent Tic Questionnaire, and Goal-Based Outcomes, with uptake, adherence, system usability, and satisfaction also measured. Adverse events were monitored throughout, and qualitative feedback was gathered via semi-structured exit interviews to inform future NHS-scale adoption.

The Video-Based Observation Study (2025) enrolled 39 youth aged 12–21 years and employed precision video-based behavioral coding to quantify tic frequency across different observational contexts before and after treatment. Participants exhibited significantly more tics when alone and ticcing naturally (mean 25.03 tics per minute [tpm]) compared to when alone with suppression instructions (mean 9.48 tpm) or in the presence of a clinician (mean 3.29 tpm; all P < 0.001). Mixed-model analyses demonstrated a significant reduction in tpm across treatment both when alone (β = −21.85; 95% CI: −33.99 to −9.70) and with a clinician present (β = −20.31; 95% CI: −35.08 to −5.55), with a significantly greater treatment-related decrease observed in the unobserved context (β = −6.01; 95% CI: −9.74 to −2.29). These findings establish objective video-based measurement as a valuable tool for detecting tics and capturing treatment-related change that may not be visible during standard clinical encounters.

A New Horizon for Pediatric Tourette Syndrome Treatment

The submission of a New Drug Application for ecopipam represents a pivotal moment for the management of pediatric Tourette syndrome. For years, clinicians and families have grappled with limited treatment options, often relying on antipsychotics that, while effective for tic reduction, carry significant side effects such as weight gain, metabolic disturbances, and movement disorders. These adverse events frequently lead to treatment discontinuation, leaving many children and adolescents without adequate relief.

Ecopipam, a selective dopamine D1 receptor antagonist, offers a distinct mechanism of action that appears to circumvent many of these challenges. Clinical trials indicate that it effectively reduces tic severity and improves quality of life in pediatric patients, notably without the weight gain or dyskinesias associated with D2 antagonists. The positive Phase 3 data, demonstrating a significant delay in time to relapse, is particularly compelling, suggesting a sustained benefit for patients. This novel approach, coupled with FDA Orphan Drug and Fast Track designations, positions ecopipam for an expedited review and potential market entry, addressing a critical unmet need and offering a new standard of care.

However, the path forward is not without considerations. Historical data from ecopipam's development for obesity revealed psychiatric adverse events, including depression and anxiety, which warrant careful monitoring in the Tourette syndrome population. Furthermore, its complex pharmacokinetic profile, involving strong CYP2D6 inhibition and weak induction of other enzymes, necessitates vigilance for potential drug-drug interactions, especially given that pediatric patients may be on multiple medications. While efficacy data show significant tic reduction, the magnitude of improvement, though clinically meaningful, highlights the need for ongoing assessment of long-term durability and real-world effectiveness. Should ecopipam gain approval, it could fundamentally reshape treatment paradigms, providing a much-needed, better-tolerated option for children and adolescents living with Tourette syndrome.